Kamari Pharma is happy to announce the initiation of a new study in the UK to evaluate the safety and efficacy of KM001-a new potential treatment for PC and PPPK1 patients.
KM001 is a novel, small molecule which acts as TRPV3 inhibitor- a protein that plays essential role in keratoderma and itch development and formulated into a topical cream.
The KM001 cream is already testing in a phase 1b study in Israel, enrolling PC and PPPK1 patients and recently a new study was initiated at Prof Edel O’Toole’s site in the Royal London Hospital. The study is a proof-of-concept study and will enroll up to 10 patients, for a treatment period of 12 weeks.
Kamari Pharma hopes that the results of these studies will be able to support further development of the KM001 topical cream, which may provide a new solution for patients with PC and PPPK1.